|Last Update: 05/22/13 - 4:02 PM EDT|
|YTD Performance: 35.48%|
|Previous Close: $50.11|
|52 Week Range: $28.53 - $51.20|
|Oustanding Shares: 947,485,297|
|Market Cap: 47,478,488,233|
|Qtr (05/13)||Qtr (08/13)||FY (08/13)||FY (08/14)|
|Number of Analysts||12||12||12||14|
|Growth Rate (Year over Year)||45.43%||53.93%||20.57%||11.38%|
Today's investment environment has more moving parts than ever.
Jim Cramer talks the "ethereal" contributions of brand power and customer service with Nicole Urken, Mad Money Research Associate.
Performance in the corner office has made these companies into leaders.
WAG was upgraded to a Buy from Sell, said Citigroup. The deal with AmerisourceBergen will transform the pharmaceutical supply chain globally. New price target is $51.
WAG was removed from the Conviction Buy list, Goldman Sachs said. Valuation call, based on the new $50 price target.
WAG was upgraded to Overweight from Neutral, JP Morgan said. $55 price target. Transforming the global supply chain with new strategic relationship.
WAG earnings estimates were increased through 2014, said UBS. The deal with ABC will enhance EPS. Price target is now $51.
A pullback followed by a short-term base here would set it up well.
For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.